76
Participants
Start Date
January 24, 2018
Primary Completion Date
February 21, 2019
Study Completion Date
September 17, 2020
PDR001
PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
LAG525
LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
University Cancer and Blood Center, LLC, Athens
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
Indiana University, Indianapolis
University of Iowa Hospitals and Clinics Comprehensive Cancer Center, Iowa City
Medical College of Wisconsin, Milwaukee
University of Wisconsin Hospital and Clinics, Madison
Billings Clinic Dept of Billings Clinic(2), Billings
Northwestern University Medical School, Chicago
University of Illinois Cancer Center at Chicago SC, Chicago
The University of Kansas Clinical Research Center, Fairway
Oncology Hematology West Nebraska Cancer Specialists, Omaha
Oncology Consultants Oncology Consultants, Houston
University of Texas - MD Anderson Cancer Center, Houston
Comprehensive Cancer Centers, Las Vegas
Oregon Health and Science University, Portland
Providence Regional Cancer System SC, Lacey
Kadlec Clinic Hematology and Oncology, Kennewick
California Pacific Medical Center Drug Shipment (2), San Francisco
Illinois Cancer Care P.C. Jesse Brown VA, Peoria
Weinberg Cancer Institute at Franklin Square Hospital, Baltimore
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY